In addition to the direct effects of SGLT2 inhibitors in improving glucose homeostasis and insulin sensitivity in diabetes patients, many large double‐blind clinical observations and a meta‐analysis revealed additional benefits in cardiovascular mortality, stroke events and kidney protection in treatment of diabetic patients (Perkovic et al., 2019; Wiviott et al., 2019; Zinman et al., 2015). The gene discussed is SLC5A2; the disease is diabetes mellitus.